ANAVEX LIFE SCIENCES CORP.
AVXL$708M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaNEW YORK
Drugs in Pipeline
6
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Jun 23, 2026
3dMarket Overview
Stock performance and key metrics
AVXL News
Catalyst Timeline
1 upcoming, 0 past
EarningsNext
AVXL Earnings Report
Jun 23, 2026Confirmed
EPS Est: $-0.07 | FQ end 2026-03
Drug Pipeline
ANAVEX2-73
Alzheimer's Disease
Mid dose ANAVEX2-73
Alzheimer Disease
ANAVEX2-73 oral liquid
Rett Syndrome
High dose ANAVEX2-73
Parkinsons Disease With Dementia
ANAVEX2-73 Oral
Alzheimer's Disease
ANAVEX3-71 oral capsules
Schizophrenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ANAVEX2-73 | Phase 3 | Alzheimer's Disease | - | - |
Mid dose ANAVEX2-73 | Phase 3 | Alzheimer Disease | - | - |
ANAVEX2-73 oral liquid | Phase 3 | Rett Syndrome | - | - |
High dose ANAVEX2-73 | Phase 3 | Parkinsons Disease With Dementia | - | - |
ANAVEX2-73 Oral | Phase 2 | Alzheimer's Disease | - | - |
ANAVEX3-71 oral capsules | Phase 2 | Schizophrenia | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply